Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...
Investor's Business Daily on MSN5d
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and ...
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Citing topline data from the trial, the company added that amycretin, a GLP-1 and amylin receptor agonist, indicated a safety profile in line with incretin-based drugs such as its FDA-approved ...
Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM ...
The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback